Physician profile
Amy Nelson
NPI 1790109338
$910.38
in general payments reported to CMS, 2019-2025
17 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.46 · 2023: $81.65 · 2024: $254 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $14.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.56 |
| Education | $14.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $192.60 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $152.09 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $106.64 | 2023-2025 | |
| Abbvie INC. | $96.51 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $82.74 | 2025 | Voquezna |
| Lilly USA, LLC | $47.55 | 2023-2025 | Mounjaro, Jardiance |
| Genentech USA, INC. | $44.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.04 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.05 | 2025 | Rexulti |
| Dexcom, INC. | $23.76 | 2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $21.45 | 2024 | |
| Abbott Laboratories | $18.43 | 2025 | Freestyle Libre 3 |
| Atland Pharmaceuticals, LLC | $14.79 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Exact Sciences Corporation | $14.15 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.79 | 2025 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $13.47 | 2024 | Nuzyra |
| Glaxosmithkline, LLC. | $12.86 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.